CAJ | 학술논문

目的：探讨促红细胞生成素( rHuEPO)改善股骨转子间骨折术后贫血的临床疗效。方法将100例符合标准的股骨转子间骨折患者随机分为实验组(50例)和对照组(50例)。实验组给予rHuEPO皮下注射治疗,对照组不给予rHuEPO治疗,余治疗相同。比较两组患者术后输血、功能恢复和并发症发生率。结果实验组6例接受输血治疗,对照组14例接受输血治疗,差异有统计学意义(14．5% vs 27．6%,P=0．04)；实验组于出院时血红蛋白水平为(108．2±10．5)g/L,对照组为(100．5±9．2)g/L,差异有统计学意义(P=0．01)；术后1、3个月实验组FIM评分分别为(85．8±13．4)分和(100．2±15．2)分,显著高于对照组的(70．0 ±15．2)分和(86．6±20．4)分(P<0．01)；并发症：实验组发生9例,对照组发生11例；两组比较差异无统计学意义(P=0．65)。结论 rHuEPO在股骨转子间骨折术后应用是安全的,并可减少输血和促进术后恢复。
목적：탐토촉홍세포생성소( rHuEPO)개선고골전자간골절술후빈혈적림상료효。방법장100례부합표준적고골전자간골절환자수궤분위실험조(50례)화대조조(50례)。실험조급여rHuEPO피하주사치료,대조조불급여rHuEPO치료,여치료상동。비교량조환자술후수혈、공능회복화병발증발생솔。결과실험조6례접수수혈치료,대조조14례접수수혈치료,차이유통계학의의(14．5% vs 27．6%,P=0．04)；실험조우출원시혈홍단백수평위(108．2±10．5)g/L,대조조위(100．5±9．2)g/L,차이유통계학의의(P=0．01)；술후1、3개월실험조FIM평분분별위(85．8±13．4)분화(100．2±15．2)분,현저고우대조조적(70．0 ±15．2)분화(86．6±20．4)분(P<0．01)；병발증：실험조발생9례,대조조발생11례；량조비교차이무통계학의의(P=0．65)。결론 rHuEPO재고골전자간골절술후응용시안전적,병가감소수혈화촉진술후회복。
Objective To determine the clinical significance of recombinant human erythropoietin ( rHuEPO) ap-plied in intertrochanteric fractures. Methods 100 patients were enrolled into the study according to the inclusion and exclusion criteria. They were randomly allocated into the study group ( n =50 ) who were administered with rHuEPO sub-cutaneous injection starting on the day of admission, the control group (n=50) without rHuEPO or any erythropoietin-like medicine. The same operation and rehabilitation regime were given to two groups. The need for al-logenic blood transfusions ( ABTs) , functional rehabilitation and complication rate were compared. Results Signifi-cant differences were observed in the percentage of patients requiring transfusion [study group 6(14. 5%) vs control group 14 (27. 6%), P=0. 04]. The mean hemoglobin levels at discharge of the study group and the control group was (108. 2 ± 10. 5) g/L and (100. 5 ± 9. 2) g/L, respectively, with a significance (P=0. 01). FIM scores at the follow-up of one month and three months were higher in patients who received rHuEPO (85. 8 ± 13. 4, 100. 2 ± 15. 2) than those who did not (70. 0 ± 15. 2, 86. 6 ± 20. 4) (P<0. 01). Overall, complications occurred in 9 cases in the study group and 11 cases in the control group, but the difference had no statistical significance (P=0. 65). Conclu-sions rHuEPO can effectively reduce the need for ABTs and accelerate the early functional recovery in patients with intertrochanteric fractures.